Home


COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.

 


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $261.6 million in 75 projects around the world.

261.6

$million

Invested

75

innovative

Projects

10

different

Countries

17

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


Spotlight on Science

Vedanta Biosciences’ new VE303 drug will prevent live-threatening C. difficile infections by boosting the body’s microbiome

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

01.21.21

 

Innovative Medicines Initiative (IMI) ENABLE Annual Meeting

01.26.21

 

4th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference

01.27.21

 

5th Microbiome Movement - Drug Development Summit Europe 2021

CARB-X News

  • 12.16.2020  |  2020 a year of remarkable progress in supporting the development of new antibiotics, vaccines, diagnostics and other products targeting antibiotic-resistant bacteria full release

  • 12.08.2020  |  CARB-X honored with award from the Global Health Technologies Coalition for progress made in accelerating R&D to combat drug-resistant bacteria full release

  • 12.01.2020  |  CARB-X is funding a German team of scientists to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients full release

See All News

In The News

  • 01.12.2021  |  Can we warp-speed antibiotic development? full story

  • 01.08.2021  |  Improving data sharing to increase the efficiency of antibiotic R&D full story

  • 12.10.2020  |  CARB-X wins prestigious award for efforts to combat antibiotic-resistant bacteria full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.